TOR1 ACTIVITY

2015 - 16
  • Research proposal for a hospital based cohort study “Cost effective non invasive diagnostic modalities and predictive model for the development and progression of fibrosis among patients with Hepatitis B, Hepatitis C infection, or non alcoholic fatty liver disease” approved
  • Retrospective cohort: 3006 cases from 2010 to 2015. [1685 cases of HBV, 532: HCV, and 789: NAFLD]
2016 - 17
  • Prospective phase began in Jan 2016: 622 cases till year end:
  • 325 NAFLD patients
  • 238 Hepatitis B cases
  • 59 Hepatitis C cases
2017 - 18
  • 640 cases:
  • 333 NAFLD patients
  • 245 Hepatitis B cases
  • 62 were Hepatitis C cases.
  • 1050 biopsies conducted for Hepatitis B cases over 4 years. 375 biopsies for HCV
2019 - 20
  • Hospital based registries initiated for Cirrhosis and Hepatocellular carcinoma patients in 13 centers of excellence in Hepatology across the country.
  • Total participants registered: 2210
  • Liver cirrhosis: 98% (51% non compensated liver cirrhosis)
  • HCC: 28%
  • HBsAg positive: 13%
  • HCV RNA positive: 6%
2020 - 21
  • Cirrhosis: 1032 (81.65)
  • Hepatocellular carcinoma: 818 (64.72)
  • Total: 1264
2021 - 22
  • Cirrhosis: 1815 (78.16)
  • Hepatocellular carcinoma: 1322 (56.93)
  • Total: 2322